MX369719B - Virus recombinantes de la enfermedad de marek y usos de los mismos. - Google Patents

Virus recombinantes de la enfermedad de marek y usos de los mismos.

Info

Publication number
MX369719B
MX369719B MX2016002891A MX2016002891A MX369719B MX 369719 B MX369719 B MX 369719B MX 2016002891 A MX2016002891 A MX 2016002891A MX 2016002891 A MX2016002891 A MX 2016002891A MX 369719 B MX369719 B MX 369719B
Authority
MX
Mexico
Prior art keywords
disease viruses
recombinant marek
recombinant
relates
marek
Prior art date
Application number
MX2016002891A
Other languages
English (en)
Other versions
MX2016002891A (es
Inventor
Sato Takanori
Esaki Motoyuki
Saitoh Shuji
Original Assignee
Ceva Sante Animale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49115425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX369719(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ceva Sante Animale filed Critical Ceva Sante Animale
Publication of MX2016002891A publication Critical patent/MX2016002891A/es
Publication of MX369719B publication Critical patent/MX369719B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16371—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a virus recombinantes y a los usos de los mismos. Más concretamente, la invención se refiere a nuevos virus recombinantes de la enfermedad de Marek que codifican polipéptido/s de interés y a su uso para expresar o administrar dichos polipéptidos a animales, en particular, a aves de corral. La invención es particularmente adecuada para la vacunación de aves de corral contra patógenos aviares.
MX2016002891A 2013-09-06 2014-09-05 Virus recombinantes de la enfermedad de marek y usos de los mismos. MX369719B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13183393.1A EP2845904A1 (en) 2013-09-06 2013-09-06 Recombinant Marek's disease viruses and uses thereof
PCT/EP2014/068964 WO2015032910A1 (en) 2013-09-06 2014-09-05 Recombinant marek's disease viruses and uses thereof

Publications (2)

Publication Number Publication Date
MX2016002891A MX2016002891A (es) 2016-06-10
MX369719B true MX369719B (es) 2019-11-20

Family

ID=49115425

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002891A MX369719B (es) 2013-09-06 2014-09-05 Virus recombinantes de la enfermedad de marek y usos de los mismos.

Country Status (12)

Country Link
US (1) US10188720B2 (es)
EP (3) EP2845904A1 (es)
CN (1) CN105765071B (es)
ES (1) ES2732828T3 (es)
HU (1) HUE045320T2 (es)
MX (1) MX369719B (es)
PL (1) PL3041939T3 (es)
PT (1) PT3041939T (es)
RU (1) RU2681889C2 (es)
TR (1) TR201909342T4 (es)
WO (2) WO2015032910A1 (es)
ZA (1) ZA201602227B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2851658C (en) 2011-10-21 2022-03-15 Intervet International B.V. Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
EP2644702A1 (en) 2012-03-30 2013-10-02 Ceva Sante Animale Multivalent recombinant avian herpes virus and vaccine for immunizing avian species
EP2845904A1 (en) 2013-09-06 2015-03-11 Ceva Sante Animale Recombinant Marek's disease viruses and uses thereof
US11596687B2 (en) 2016-06-17 2023-03-07 Intervet Inc. Recombinant non-pathogenic Marek's disease virus constructs encoding infectious laryngotracheitis virus and infectious bursal disease virus antigens
CN117357642A (zh) 2016-12-14 2024-01-09 勃林格殷格翰动物保健美国公司 表达禽病原体的多种抗原的重组hvt载体及其用途
BR112020007213A2 (pt) 2017-10-12 2020-10-13 Intervet International B.V. construtos de vírus da doença de marek não patogênico recombinante que codificam múltiplos antígenos heterólogos
BR112021012434A2 (pt) * 2018-12-27 2021-09-28 Ceva Sante Animale Vírus recombinantes e usos dos mesmos
CN110331135A (zh) * 2019-07-18 2019-10-15 扬州大学 表达基因vii型新城疫病毒融合蛋白的重组火鸡疱疹病毒候选疫苗株及制备方法
EP4378474A2 (en) 2020-06-17 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Recombinant hvt vectors expressing influenza hemagglutinin and immunogenic compositions, and production and uses thereof
CN111910019A (zh) * 2020-08-04 2020-11-10 广东省实验动物监测所 一种检测鸡传染性喉气管炎病毒rpa扩增方法
JP2023545524A (ja) * 2020-10-15 2023-10-30 セヴァ サンテ アニマレ 組換えｈｖｔ及びその使用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004463A1 (en) 1986-01-27 1987-07-30 Syntro Corporation Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same
ES2056565T3 (es) * 1990-07-30 1994-10-01 Akzo Nobel Nv Virus recombinante de la enfermedad de marek.
BE1004877A3 (fr) 1991-05-27 1993-02-16 Solvay Virus de l'avipox recombinant, culture de cellules infectees par ce virus et vaccins pour la volaille derives de ce virus.
US5853733A (en) 1993-02-26 1998-12-29 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
FR2728795B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
FR2728794B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
JPH08322559A (ja) * 1995-06-02 1996-12-10 Chemo Sero Therapeut Res Inst ｇＢ遺伝子プロモーターを用いた組換えヘルペスウイルス
FR2750866B1 (fr) * 1996-06-27 1998-11-27 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
EP1026246B1 (en) * 1997-10-03 2006-11-29 Zeon Corporation Avian infectious herpesvirus recombinants and recombinant vaccines prepared with the use of the same
US6495360B1 (en) * 1999-05-28 2002-12-17 Photogen, Inc. Method for enhanced protein stabilization and for production of cell lines useful for production of such stabilized proteins
WO2001005988A1 (en) * 1999-07-16 2001-01-25 Merial Select, Inc Live recombinant vaccine against avian leukosis virus using a marek's disease virus (mdv) virus as vector
AU1466301A (en) 1999-11-04 2001-05-14 Advanced Sensor Technologies, Inc. Microscopic multi-site sensor array with integrated control and analysis circuitry
RU2205660C2 (ru) * 2001-08-14 2003-06-10 Федеральное государственное учреждение Всероссийский научно-исследовательский институт защиты животных Вирусвакцина против болезни марека
US6764684B2 (en) 2001-09-28 2004-07-20 Zeon Corporation Avian herpesvirus-based recombinant infectious bursal disease vaccine
US6866852B2 (en) 2002-01-31 2005-03-15 Zeon Corporation Recombinant herpesvirus of turkeys and use thereof
JP4010356B2 (ja) * 2002-05-22 2007-11-21 日本製紙株式会社 植物ウイルス由来プロモーター
JPWO2005093070A1 (ja) * 2004-03-29 2008-02-14 日本ゼオン株式会社 組み換えヘルペスウイルス及びその利用
JP2005287422A (ja) * 2004-03-31 2005-10-20 Nippon Zeon Co Ltd 組み換えヘルペスウイルス及び多価ワクチン
JP2008228658A (ja) * 2007-03-20 2008-10-02 Nippon Zeon Co Ltd 新規なプロモーター、これを有する組み換え七面鳥ヘルペスウイルス、及びこれを利用した家禽用ワクチン
CN101121938B (zh) * 2007-03-23 2010-10-06 中国农业科学院兰州兽医研究所 一种口蹄疫抗原的制备方法
CN101575616B (zh) * 2007-10-25 2011-08-31 扬州大学 禽流感和马立克氏病二联活疫苗rMDV-HA病毒株及构建方法
US20090246226A1 (en) 2008-03-28 2009-10-01 Zeon Corporation Avian vaccines possessing a positive marker gene
CN101343624B (zh) * 2008-06-25 2014-05-21 浙江中奇生物药业股份有限公司 一种重组人生长激素基因的杆状病毒及其制备方法与应用
CN105567648B (zh) * 2009-04-15 2019-09-03 法国诗华大药厂 用于免疫接种水禽物种的重组禽疱疹病毒载体和疫苗
GB0914826D0 (en) * 2009-08-25 2009-09-30 Wyeth Corp Assay methods
CN102041263B (zh) * 2010-02-08 2013-01-09 河南省动物疫病预防控制中心 鸡α干扰素/白细胞介素2嵌合基因
BR112014008161A2 (pt) * 2011-10-21 2017-04-11 Intervet Int Bv vírus da doença de marek não patogênico recombinante, método para a preparação do mesmo, molécula do ácido nucleico, célula hospedeira, vacina para aves domésticas, método para a preparação de uma vacina, uso de um vírus da doença de marek não patogênico recombinante, e, método de vacinação de aves domésticas
CA2851658C (en) * 2011-10-21 2022-03-15 Intervet International B.V. Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
LT3251691T (lt) * 2011-11-30 2020-02-10 Boehringer Ingelheim Animal Health USA Inc. Rekombinantiniai hvt vektoriai, ekspresuojantys paukščių patogenų antigenus, ir jų panaudojimas
EP2644702A1 (en) * 2012-03-30 2013-10-02 Ceva Sante Animale Multivalent recombinant avian herpes virus and vaccine for immunizing avian species
CN103131795B (zh) * 2013-01-15 2014-05-07 北京华都诗华生物制品有限公司 鉴别马立克氏病病毒血清1型疫苗毒的引物及试剂盒
EP2845904A1 (en) 2013-09-06 2015-03-11 Ceva Sante Animale Recombinant Marek's disease viruses and uses thereof
CN103740759B (zh) * 2014-01-20 2016-04-06 中国农业科学院哈尔滨兽医研究所 表达h5n1亚型禽流感病毒ha基因的重组火鸡疱疹病毒

Also Published As

Publication number Publication date
EP3524682A1 (en) 2019-08-14
RU2681889C2 (ru) 2019-03-13
EP2845904A1 (en) 2015-03-11
EP3041939A1 (en) 2016-07-13
US20160220657A1 (en) 2016-08-04
ES2732828T3 (es) 2019-11-26
HUE045320T2 (hu) 2019-12-30
CN105765071A (zh) 2016-07-13
PL3041939T3 (pl) 2019-12-31
PT3041939T (pt) 2019-07-10
MX2016002891A (es) 2016-06-10
EP3041939B1 (en) 2019-03-27
CN105765071B (zh) 2021-02-26
WO2015032910A1 (en) 2015-03-12
ZA201602227B (en) 2017-06-28
TR201909342T4 (tr) 2019-08-21
RU2016112951A (ru) 2017-10-11
US10188720B2 (en) 2019-01-29
WO2015032909A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
MX369719B (es) Virus recombinantes de la enfermedad de marek y usos de los mismos.
SA518390954B1 (ar) لقاحات علاجية لفيروس الورم الحليمي البشري 18
ECSP17043316A (es) Polvo de coleópteros
TW201613556A (en) Swine virus vaccines that are liquid stable
PH12018501882A1 (en) Binding proteins and methods of use thereof
MX2016010651A (es) Vacunas de virus aviar que son estables en liquido.
EA201791426A1 (ru) Полипептид и иммуномодуляция
MX2017014730A (es) Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3).
WO2015020913A3 (en) Influenza hemagglutinin proteins and methods of thereof
UY34860A (es) Sistema de expresión en cho.
PE20171076A1 (es) Composicion que contiene quitina y proteinas digeribles
MX2016015235A (es) Nuevos polipeptidos de union especifica y usos de los mismos.
MX2017000378A (es) ANTICUERPOS DE UNION A PROTOFIBRILLAS BETA AMILOIDE (Aß) MEJORADOS.
MX2016014633A (es) Nuevos derivados de cath2.
DK3146042T3 (da) Rekombinant klassisk svinepestvirus (CSFV) med substitution i E2-proteinets TAV-epitop
PH12017500156A1 (en) Angiopoietin-like 4 antibodies and methods of use
MX2018016306A (es) Virus de enteritis de pato y usos del mismo.
BR112015018265A2 (pt) Composições nutricionais contendo um componente peptídico com propriedades estimulantes de adiponectina e utilizações das mesmas
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
UA122339C2 (uk) Вірус качиного ентериту та його застосування
MX2021007761A (es) Virus recombinantes y sus usos.
MY178931A (en) Polypeptides with permease activity
EA201691140A1 (ru) Иммуногенные композиции и вакцины, полученные из рецепторных белков поверхности бактерий
MX2017009796A (es) Mdv1 recombinantes y usos de los mismos.
EP3606948A4 (en) IDENTIFICATION OF CYCLIC PEPTIDIC AGONISTS OF GALANINE RECEPTOR 2 AND 3 GUIDED BY A SPEXIN SOLUTION STRUCTURE

Legal Events

Date Code Title Description
FG Grant or registration